Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linezolid Pharmacia Corp.

J F Barrett1

  • 1Pharmaceutical Research and Development Division, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA. john.barrett@bms.com

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

Linezolid, an oxazolidinone antibiotic, treats multi-resistant Gram-positive infections by inhibiting bacterial protein synthesis. Resistance can emerge due to specific mutations, potentially leading to treatment failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maternal outcomes at 3 months after planned caesarean section versus planned vaginal birth for twin pregnancies in the Twin Birth Study: a randomised controlled trial.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Bacterial resistance.

IDrugs : the investigational drugs journal·2005
Same author

Quinolone update.

IDrugs : the investigational drugs journal·2005
Same author

Targets, targets everywhere--so where are the new antibacterial drugs?

IDrugs : the investigational drugs journal·2005
Same author

American Society of Microbiology - 100th General Meeting.

IDrugs : the investigational drugs journal·2005
Same author

Antifungal agents and efflux pump inhibitors.

IDrugs : the investigational drugs journal·2005

Area of Science:

  • Pharmacology
  • Microbiology

Background:

  • Linezolid is an oxazolidinone antibiotic developed for treating multi-resistant Gram-positive bacterial infections.
  • It functions by binding to the 50S ribosomal subunit, inhibiting the initiation of protein translation.

Purpose of the Study:

  • To provide an overview of linezolid's development, mechanism of action, and approved indications.
  • To highlight potential resistance mechanisms and clinical implications.

Main Methods:

  • Literature review of linezolid's pharmacological properties and clinical applications.
  • Analysis of FDA approvals and market predictions.

Main Results:

  • Linezolid received FDA approval in April 2000 for various Gram-positive infections, including VRE and MRSA.
  • Resistance may develop through 23S rRNA mutations, impacting treatment efficacy.
  • Market sales projections indicated significant commercial potential.

Conclusions:

  • Linezolid is a crucial therapeutic option for challenging Gram-positive infections.
  • Monitoring for resistance is essential for effective linezolid therapy.
  • The drug demonstrated substantial market potential upon its release.

Related Experiment Videos